Form 4: ADial Pharmaceuticals Director Acquires Shares

Kevin Schuyler, a Director at ADial Pharmaceuticals, Inc., has acquired 9,185 shares of common stock through a restricted stock grant.

Summary

• Kevin Schuyler, a Director at ADial Pharmaceuticals, Inc. (ADIL), reported a transaction on April 7, 2026.
• He acquired 9,185 shares of common stock via a restricted stock grant.
• These shares vest in full one year after the grant date or upon a Change of Control, provided he remains in service.
• Following this transaction, Mr. Schuyler directly beneficially owns 9,213 shares.
• Additionally, he indirectly beneficially owns shares through his wife and MVA 151 Investors, LLC, over which he has control.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, indicating continued commitment and alignment, but does not provide new financial performance data.

Positives

• Director Kevin Schuyler received a grant of 9,185 restricted shares, indicating continued investment and alignment with the company's performance.
• The restricted stock grant vests over time, incentivizing continued service and commitment to ADial Pharmaceuticals.
• Mr. Schuyler's indirect beneficial ownership through his wife and a controlled LLC suggests broader personal investment in the company.

Risks

• The restricted shares are subject to forfeiture if Mr. Schuyler's continued service to the Issuer is not maintained through the vesting date.
• A Change of Control event is a trigger for full vesting, implying potential future uncertainty regarding the company's ownership structure.

Future Outlook

The restricted shares granted to Mr. Schuyler will vest in full on the earlier of the one-year anniversary of the grant date or a Change of Control, contingent upon his continued service.

Industry Context

StockSavvy.ai notes that insider grants of restricted stock, as seen with ADial Pharmaceuticals Director Kevin Schuyler, are common mechanisms for executive compensation and retention within the biotechnology and pharmaceutical sectors, aligning management interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The filing details a transaction involving Director Kevin Schuyler, a related party by virtue of his position.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with long-term company performance and shareholder value.
• Employees: May signal stability and commitment from leadership.
• Management: Reinforces the use of equity-based compensation as a retention tool.

Next Steps

• Vesting of restricted shares on the earlier of the one-year anniversary of the grant date or a Change of Control.
• Continued service by Mr. Schuyler to ADial Pharmaceuticals through the vesting date.

Key Dates

Keywords

ADial Pharmaceuticals, ADIL, Form 4, SEC Filing, Insider Trading, Restricted Stock, Director, Beneficial Ownership, Equity Incentive Plan, Kevin Schuyler